Explore
Validate
Learn15627-1-AP
antibody from Proteintech Group
Targeting: EXOSC5
hRrp46p, MGC12901, p12B, RRP41B, RRP46, Rrp46p
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15627-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15627-1-AP, RRID:AB_2293809
- Product name
- EXOSC5 antibody
- Antibody type
- Polyclonal
- Description
- EXOSC5 antibody (Cat. #15627-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, rat and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Suppressor of cytokine signaling 6 (SOCS6) mediates ubiquitination degradation of SLC7A11 to drive ferroptosis and block lipid metabolism in ovarian cancer cells.
EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.
Dual modes of ZFC3H1 confer selectivity in nuclear RNA sorting.
Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication.
EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways.
Integrated Bioinformatic Investigation of EXOSCs in Hepatocellular Carcinoma Followed by the Preliminary Validation of EXOSC5 in Cell Proliferation.
Fan Y, Suo Y
Gene 2025 Nov 5;971:149819
Gene 2025 Nov 5;971:149819
EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.
Xu J, Zhang Z, Han K, Yang Z, Guo F
BMC cancer 2025 Apr 14;25(1):681
BMC cancer 2025 Apr 14;25(1):681
Dual modes of ZFC3H1 confer selectivity in nuclear RNA sorting.
Fan J, Wang Y, Wen M, Tong D, Wu K, Yan K, Jia P, Zhu Y, Liu Q, Zou H, Zhao P, Lu F, Yun C, Xue Y, Zhou Y, Cheng H
Molecular cell 2024 Nov 21;84(22):4297-4313.e7
Molecular cell 2024 Nov 21;84(22):4297-4313.e7
Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication.
Moll T, Odon V, Harvey C, Collins MO, Peden A, Franklin J, Graves E, Marshall JN, Dos Santos Souza C, Zhang S, Castelli L, Hautbergue G, Azzouz M, Gordon D, Krogan N, Ferraiuolo L, Snyder MP, Shaw PJ, Rehwinkel J, Cooper-Knock J
Life science alliance 2023 Jan;6(1)
Life science alliance 2023 Jan;6(1)
EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways.
Chen X, Huang Y, Liu J, Lin W, Chen C, Chen Y, Ding Y, Yang Y, Chen Y, Wang H, Teng L
Journal of Cancer 2022;13(5):1456-1467
Journal of Cancer 2022;13(5):1456-1467
Integrated Bioinformatic Investigation of EXOSCs in Hepatocellular Carcinoma Followed by the Preliminary Validation of EXOSC5 in Cell Proliferation.
Zhang Y, Yang X, Hu Y, Huang X
International journal of molecular sciences 2022 Oct 12;23(20)
International journal of molecular sciences 2022 Oct 12;23(20)
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- K-562 cells were subjected to SDS PAGE followed by western blot with 15627-1-AP(EXOSC5 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 15627-1-AP(EXOSC5 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The EXOSC5 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human EXOSC5. This antibody recognizes human, rat antigen. The EXOSC5 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
